P6523
N-Propionylprocainamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C16H25N3O2
CAS Number:
Molecular Weight:
291.39
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
InChI
1S/C16H25N3O2/c1-4-15(20)18-14-9-7-13(8-10-14)16(21)17-11-12-19(5-2)6-3/h7-10H,4-6,11-12H2,1-3H3,(H,17,21)(H,18,20)
SMILES string
CCN(CC)CCNC(=O)c1ccc(NC(=O)CC)cc1
InChI key
CTHPVGZIOICAFO-UHFFFAOYSA-N
storage temp.
−20°C
Looking for similar products? Visit Product Comparison Guide
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Anusha Balla et al.
Pharmaceutics, 10(2) (2018-03-31)
A simple, sensitive, and reliable reversed-phase, Ultra-High-Pressure Liquid Chromatography (UHPLC) coupled with a Diode Array Detector (DAD) method for the simultaneous determination of Procainamide (PA) and its major metabolite, N-acetylprocainamide (NAPA), in rat plasma was developed and validated. A simple
[A new anti-arrhythmia drug. I. Study of the anti-arrhythmia effects of a new N-acyl derivative of procainamide in rabbits].
J Kusowska
Acta poloniae pharmaceutica, 45(4), 346-350 (1988-01-01)
J Kusowska
Acta poloniae pharmaceutica, 46(1), 90-97 (1989-01-01)
In the recent years a remarkable number of new antiarrhythmic drugs have been introduced, but their side effects limit the application. Procainamide (PA) and N-acetylprocainamide (Acekainide, NAPA) display many undesired side effects, too. It was assumed that N-propionyl-procainamide, having antiarrhythmic
J Kusowska et al.
Acta poloniae pharmaceutica, 46(2), 187-194 (1989-01-01)
Procainamide (PA) often applied in cases of ventricular arrhythmias causes numerous cardiac and extracardiac undesirable symptoms. Its active metabolite, N-acetylprocainamide (NAPA; Acecainide) is known to affect less noxiously the ventriculo-atrial conduction and the intraventricular++ conduction, and it does not impair
Yoo-Seong Jeong et al.
Pharmaceutics, 11(3) (2019-03-09)
Previous observations demonstrated that cimetidine decreased the clearance of procainamide (PA) and/or N-acetylprocainamide (NAPA; the primary metabolite of PA) resulting in the increased systemic exposure and the decrease of urinary excretion. Despite an abundance of in vitro and in vivo
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service